Roberto Cuca

“I'm happy to review our financial results for the second quarter. First, from the top line perspective, we delivered total revenue of $57.6 million in the second quarter of '21 compared to $29.3 million in the prior year, representing year-over-year growth of 97%.”

“Our first quarter net revenues increased 85% to $58.6 million from the $31.6 million we reported in the first quarter of 2020, primarily as a result of strong sales of molecular sample collection kits for COVID-19 testing, higher genomics product sales, and increased sales of our over-the-counter OraQuick In-Home HIV…”

“As Steve mentioned earlier, our fourth quarter net revenues increased 27% to $62.9 million from the $49.7 million reported in the fourth quarter of 2019, primarily as a result of strong sales of molecular sample collection kits for COVID-19 testing and increased international sales of the company's HIV self-test.”

“As Steve mentioned earlier, our third quarter net revenues increased 33% to $48 million from the $36 million reported in the third quarter of 2019, primarily as a result of strong sales of molecular sample collection kits for COVID-19 testing, increased international sales of the company's HIV self-test, and higher…”

“Net product and service revenues for the three months ending June 30, 2020, dropped 24% compared to the same period in 2019, largely due to decreased sales of our genomics products caused by the timing of orders from one of our largest genomics customers and the effects of the COVID-19 pandemic.”